Nine Point Two Capital LLC Apellis Pharmaceuticals, Inc. Transaction History
Nine Point Two Capital LLC
- $252 Million
- Q4 2023
Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
299Shares Held
111MCall Options Held
2.63MPut Options Held
845K-
Avoro Capital Advisors LLC New York, NY12.2MShares$236 Million5.68% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$230 Million17.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$194 Million0.01% of portfolio
-
Morgan Stanley New York, NY9.63MShares$186 Million0.02% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$112 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.12B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...